Genetronics Biomedical Corporation

March 23, 2005 06:00 ET

Genetronics Awarded Patent for Vascular Therapy


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: GENETRONICS BIOMEDICAL CORPORATION

AMEX SYMBOL: GEB

MARCH 23, 2005 - 06:00 ET

Genetronics Awarded Patent for Vascular Therapy

SAN DIEGO--(CCNMatthews - Mar 23, 2005) -

Genetronics Biomedical Corporation (AMEX:GEB), a late stage developer of
oncology and other therapies using electroporation to deliver drugs and
nucleic acids, announced today that its subsidiary, Genetronics, Inc.,
has been granted another patent for a vascular application of its
technology, namely U.S. Patent Number 6,865,416, entitled "Electrically
Induced Vessel Vasodilation." The patent adds to Genetronics' position
as a pioneer in the use of electroporation therapy, without drugs, to
achieve vasodilation.

Electroporation refers to the application of electrical pulses to a
target tissue to temporarily increase the permeability of biological
membranes. This patent was granted for the invention that brief
electrical pulses of relatively high field strength applied to blood
vessels cause a widening of the inner diameter (the lumen) of the
treated vessels. This allows for enhanced blood flow while lowering
local blood pressure. This procedure may have the potential to be
beneficially applied to patients who suffer from partially or totally
blocked arteries or veins, either by administering electrical field
pulses by themselves or in conjunction with angioplasty.

The greatest potential for a clinical procedure of this nature would be
to treat arteries of the heart and limbs. About 1,200,000 angioplasty
procedures involving blood vessels of the heart or limbs are performed
annually in the U.S. About the same number of procedures are performed
in Europe. Blocked blood vessels are presently treated by mechanical
removal of the blocking plaque or tissue (e.g. by angioplasty) or by the
infusion of certain drugs. Genetronics' procedure, which would be
administered using a catheter with built-in electrodes and not require
drugs, has the advantage of exerting an immediate positive effect on the
blood flow without injuring the blood vessel and avoiding unwanted side
effects caused by drugs.

"This patent covers an important medical need in the cardiovascular
market, and highlights the versatility of our electrical pulse
technology. The ingenuity of our scientists to create a unique vascular
catheter design highlights our continuing efforts to seek new
applications and expand the intellectual property for our technology,"
said Avtar Dhillon, MD, Genetronics' president and CEO.

About Genetronics Biomedical Corporation

Genetronics Biomedical Corporation is a late stage biomedical company
focused on building an oncology franchise based on its proprietary
electroporation therapy. The therapy targets a significant unmet
clinical need: the selective killing of cancer cells and local ablation
of solid tumors while preserving healthy tissue. The company is moving
its lead product, the MedPulser® Electroporation Therapy System,
through pre-marketing studies for head and neck cancer and skin cancer
in Europe, where it has CE Mark accreditation, and a U.S. Phase III
pivotal study for recurrent head and neck cancer. Merck, Vical, Chiron,
the U.S. Navy, and other partners are employing Genetronics'
electroporation technology, which enhances local delivery and cellular
uptake of useful biopharmaceuticals, in their development of novel DNA
vaccines and gene therapies. Genetronics is a leader in electroporation,
with over 240 patents worldwide that are issued, allowed or pending.
More information can be obtained at www.genetronics.com.

This press release contains certain forward-looking statements relating
to Genetronics' plans to develop its electroporation drug and gene
delivery technology and to maximize shareholder value. Actual events or
results may differ from Genetronics' expectations as a result of a
number of factors, including the uncertainties inherent in clinical
trials and product development programs, evaluation of potential
opportunities, the level of corporate expenditures, the assessment of
Genetronics' technology by potential corporate partners, capital market
conditions, and other factors set forth in the Genetronics' Annual
Report on Form 10-K for the 12-month period ended December 31, 2004, and
other regulatory filings. There can be no assurance that any product in
the Genetronics product pipeline will be successfully developed or
manufactured, or that final results of clinical studies will be
supportive of regulatory approvals required to market licensed products.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Genetronics Biomedical Corporation
    Bernie Hertel, 858-410-3101 (Investor Relations)
    or
    Atkins + Associates
    Rebecca Wong, 858-527-3495 (Media Relations)